Gritstone bio, Inc. (GRTS)

$ 11.12
+0.28 (+2.58%)
-
Symbol GRTS
Price $ 11.12
Beta 0.058
Volume Avg. 1.04M
Market Cap 0.756B
Shares () -
52 Week Range 2.86-35.2
1y Target Est -
DCF Unlevered GRTS DCF ->
DCF Levered GRTS LDCF ->
ROE -38.51% Strong Sell
ROA -26.72% Sell
Operating Margin -
Debt / Equity 30.45% Neutral
P/E -
P/B 4.16 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GRTS news


Dr. Andrew Allen
Healthcare
Biotechnology
Nasdaq Global Select

Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company is headquartered in Emeryville, California and currently employs 164 full-time employees. The firm focuses to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop treatments for lung cancer. The company provides Gritstone EDGE, which is a tumor-specific neo-antigen (TSNA) prediction platform that predicts the presence of a patient’s TSNA on tumor cells. The company also develops and manufactures a patient-specific therapeutic to direct a robust thymus (T) cell response to those TSNA predicted to be presented on the patient’s tumor. In its GRANITE-001 product candidate each of the viral prime and RNA boost immunizations contain a patient-specific set of predicted TSNA, and the viral prime and RNA boost in its SLATE product candidate series contains a fixed TSNA cassette that is designed for the subset of patients with tumor neoantigens.